Search results
Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial
Medscape· 3 days agoResults from the phase 3 SELECT-GCA study showed that the Janus kinase (JAK) inhibitor upadacitinib...
Euronet Worldwide, Inc. (NASDAQ:EEFT) Given Average Rating of “Moderate Buy” by Analysts
ETF DAILY NEWS· 13 hours agoEuronet Worldwide, Inc. (NASDAQ:EEFT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports ...
Real-World RA Data Find JAK Inhibitor Infection Risk Is Low
Medscape· 3 days agoIn patients with rheumatoid arthritis (RA), Janus kinase inhibitors (JAKi) are associated with a...
Finally: ‘Inside Out 2’ and ‘Bad Boys: Ride or Die’ Take Theaters Off Life Support
Indiewire via Yahoo News· 20 hours ago...: $3,472,000 I Saw the TV Glow (A24) Week 7; also on PVOD $164,509 in 155 (-72) theaters;...
Topical Treatment Effective for Young Kids Up to 52 Weeks
Medscape· 10 hours agoNo treatment-related interruptions, discontinuations, or serious adverse events were observed with...
Adobe Inc. (NASDAQ:ADBE) Downgraded by Melius Research
Insider Monkey via Yahoo Finance· 6 days agoWe recently compiled the list of the Analysts on Wall Street Lower Ratings for These 10 Stocks. In...
From Slip-On Flats to Loafers, Fendi’s Spring 2025 Men’s Shoe Offering Goes Preppy
Footwear News via Yahoo News· 1 day agoAlong with the squirrel, the Italian luxury brand’s accessories and men’s artistic director was...
Bill Gross Sells Stamps Worth $18 Million in New York Auction
Bloomberg· 2 days agoHave a confidential tip for our reporters? Bond billionaire Bill Gross auctioned 100 stamps worth...
Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $45.00 at Bank of America
ETF DAILY NEWS· 3 days agoAvidity Biosciences (NASDAQ:RNA – Free Report) had its target price hoisted by Bank of America from $40.00 to $45.00 in a research report sent to investors on Thursday morning, Benzinga reports ...
Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Target Price at $20.80
ETF DAILY NEWS· 6 days agoShares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com ...